BLU-945 is a small molecule commercialized by Blueprint Medicines, with a leading Phase II program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of BLU-945’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for BLU-945 is expected to reach an annual total of $80 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
BLU-4810 is under development for the treatment of EGFR positive treatment resistant non-small cell lung cancer. It is administered through oral route. It acts by targeting T790M/C797S mutated EGFR receptor.
Blueprint Medicines Overview
Blueprint Medicines, formerly Hoyle Pharmaceuticals, is precision therapy company that inventing medicines for people with cancer and blood disorders. The company product pipeline includes AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST) and GAVRETO (pralsetinib) against non-small cell lung cancer in adults, BLU-263 targeting indolent systemic mastocytosis. It also offer GAVRETO, BLU-701, BLU-945, BLU-451, BLU-222 and BLU-852. Blueprint Medicines is advancing pralsetinib inhibitor against RET (Ret Proto-Oncogene) modified medullary thyroid carcinoma and other solid tumors and avapritinib to treat advanced systemic mastocytosis. The company utilizes its discover which combines bioinformatics and drug design capabilities to develop its medicines. Blueprint Medicines is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$204 million for the fiscal year ended December 2022 (FY2022), an increase of 13.3% over FY2021. The operating loss of the company was US$537.5 million in FY2022, compared to an operating loss of US$642 million in FY2021. The net loss of the company was US$557.5 million in FY2022, compared to a net loss of US$644.1 million in FY2021.
For a complete picture of BLU-945’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.